Oct. 7, 2020 — FDA Commissioner Stephen Hahn, MD, says no COVID-19 vaccine will be approved without input from its vaccine advisory panel — a step that will slow the process down and require public comment. That step will be required whether a drugmaker seeks approval for an emergency use authorization or through the regular approval… Read More: FDA Chief Says Panel Must Review COVID Vaccine »
Pfizer CEO Albert Bourla and his vaccine partner BioNTech have said the companies expect phase 3 data by the end of October—and that an FDA application could soon follow. But more than 60 researchers and bioethicists urged the partners to wait for more safety data before submitting their shot for a green light, Bloomberg reports. The experts called on… Read More: Pfizer urged to hold off on coronavirus vaccine until late… »
According to a study carried out by Lloyds Pharmacy 46% of Irish adults said they are planning on getting the flu vaccine this year. Research shows, 74 per cent of adults claim that the COVID-19 pandemic has made them more aware of the importance of being vaccinated against viruses. However, 46 per cent of adults… Read More: Less than half of Irish adults will get flu vaccine… »
Moderna’s coronavirus vaccine deal with the U.S., announced last week with a $ 1.525 billion price tag, would be worth far more if all options are exercised—and if the mRNA biotech meets an aggressive timeline for the shot’s arrival. The company stands to gain up to a whopping $ 8.125 billion, according to a Moderna… Read More: Moderna stands to earn $300M for quick vaccine approval, up… »